What To Know
- “The LinQ system from PainTEQ is the Gold Standard for SIJ dysfunction, and it brings me great joy to know I am part of a team that creates true quality-of-life benefits for these patients.
- “The addition of Michael Enxing is a big win for PainTEQ and the SIJ market.
PainTEQ the creator of LinQ, a minimally invasive therapy for SI joint (SIJ) dysfunction, announced the appointment of Michael Enxing, former Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division, as its President.
“I am excited about joining PainTEQ and aiding in the continued successful commercialization of the company,” stated Enxing. “I have always been passionate about patient care and the importance of developing clinical and commercial excellence that delivers safety, efficacy and durability for patients everywhere.”
Michael Enxing joined PainTEQ’s board of directors in July 2020 and immediately began adding substantial medical device business expertise to help accelerate PainTEQ’s market growth. With nearly three decades of executive sales and marketing management experience, Enxing has continued to provide the strategic insight necessary to ensure long-term success.
“The addition of Michael Enxing is a big win for PainTEQ and the SIJ market. Mr. Enxing’s expertise in identifying opportunities and executing them in the market has been well documented,” stated Sean LaNeve, CEO of PainTEQ. “Our goal of putting LinQ into physicians’ practices across the country to help more patients suffering from SIJ dysfunction will be greatly accelerated with this exciting new hire.”
“The LinQ system from PainTEQ is the Gold Standard for SIJ dysfunction, and it brings me great joy to know I am part of a team that creates true quality-of-life benefits for these patients. I look forward to supporting Sean and PainTEQ’s dedicated physician partners in making a difference,” stated Enxing.
“I am excited to work closely with Michael as we continue building a world-class medical device company focused on patient care,” LaNeve stated.